Doug Williamson, M.D.
Chief Medical Officer & Vice President for Lundbeck U.S. Drug Development
Care for Your Mind acknowledges and appreciates the collaboration of the American Brain Coalition in developing this series.
The world’s quietest healthcare crisis is one that starts between the ears.
When it comes to mental illness, the statistics are nearly too staggering to process. For instance, today, depression alone costs Americans an estimated $210 billion dollars each year, as millions of patients across the country struggle with a range of disabling symptoms – from loss of energy to insomnia to poor concentration – as well as massive lost productivity in the classroom, in the workforce, and on the home front. Meanwhile, while we are making such incredible strides in our treatment of cancer, Hepatitis C, HIV, and many other diseases, the tragedy and expense of mental illness accumulates by the day. According to the World Health Organization, by 2030, depression will be the leading global burden of disease.
Lundbeck, a global pharmaceutical companies focused solely on the brain, has remained steadfast in our vision of improving the lives of people suffering from psychiatric and neurological disorders. In recent years, many other companies have scaled back their R&D (Research and Development) in central nervous system (CNS) disorders, if they haven’t abandoned the space entirely. As a community invested in mental health, we have to bring them back and entice others to join the fight for better CNS treatments, especially if we want to bend the curve in challenging disease areas like depression.Read More